Liquid Embolic Market Projected to Reach USD 580.5 Million by 2031, Growing at 8.9% CAGR | Persistence Market Research

Overview of the Liquid Embolic Market

The liquid embolic market is primarily focused on embolotherapy, a medical procedure used to block blood vessels to treat a variety of conditions such as aneurysms, tumors, and vascular malformations. Liquid embolic agents, such as n-Butyl Cyanoacrylate (NBCA) and Onyx (ethyl vinyl alcohol copolymer), are essential tools in these minimally invasive procedures. These agents are delivered via catheter into the affected blood vessels, where they harden and obstruct blood flow, effectively treating the condition.

In 2020, the global liquid embolic market was valued at approximately USD 231.9 million, with projections to reach USD 580.5 million by 2031, representing a strong growth trajectory. This growth can be attributed to a variety of factors, including the rising prevalence of diseases that require embolization therapy, improvements in liquid embolic products, and increasing awareness and acceptance of minimally invasive procedures.

Get a Sample PDF Brochure of the Report (Use Corporate Email ID for a Quick Response): https://www.persistencemarketresearch.com/samples/25513

Key Highlights from the Report:

• Liquid embolic products are increasingly being used for treating brain arteriovenous malformations (bAVM).
• The liquid embolic market is projected to grow at a CAGR of 8.9% from 2021 to 2031.
• The U.S. holds a dominant market share in the North American liquid embolic market.
• Liquid embolic vials dominate the market, with a 82.7% share.
• Tumor embolization procedures are expected to drive growth in liquid embolic product demand.
• Research and development advancements are contributing to emerging market opportunities.

Market Segmentation: Understanding the Key Categories

Product Type

The liquid embolic market is largely segmented based on product type. Two primary categories dominate this space: liquid embolic vials and liquid prefilled injectables. Among these, liquid embolic vials have the largest market share, accounting for approximately 82.7% of the global market. These vials offer several advantages, including ease of use for large-volume treatments and smaller storage requirements compared to individual small-volume vials. The environmental friendliness of the packaging is another factor contributing to the widespread adoption of liquid embolic vials.

End-User Segmentation

Hospitals are the primary end-users of liquid embolic products, representing over 60% of the market share. This is primarily due to the large volume of patients requiring embolization procedures for conditions such as cancer, bAVM, and cardiovascular diseases. The increasing number of patients seeking treatment in hospitals is a key factor driving demand for liquid embolic products. In addition, healthcare systems globally are investing in advanced embolotherapy technologies to improve patient outcomes, further boosting the adoption of these products.

Regional Insights: A Look at Global Trends

North America

The U.S. is the largest market for liquid embolics, accounting for approximately 79.9% of the North American market in 2021. The dominance of the U.S. can be attributed to the increasing prevalence of chronic diseases, such as high blood pressure, migraines, and bAVM, all of which drive demand for liquid embolic therapies. Furthermore, the widespread adoption of minimally invasive treatments and advanced healthcare infrastructure continue to support market growth.

Europe

Germany stands out as the leading market for liquid embolic products in Europe, holding a 23.7% share of the regional market in 2021. The country's extensive research and development activities, particularly in cancer treatments, contribute significantly to its growth. Germany's active participation in clinical trials and the government's support for innovation make it an attractive market for liquid embolic product manufacturers. This trend is expected to continue, with Germany projected to experience a CAGR of 8% during the forecast period.

Market Drivers: Fueling Growth in the Liquid Embolic Sector

The growth of the liquid embolic market is driven by several factors:

1. Rising Prevalence of Target Diseases: As the global incidence of diseases such as cancer, cardiovascular disorders, and neurological conditions like brain arteriovenous malformations increases, so does the demand for liquid embolic therapies. Tumor embolization, in particular, is gaining traction due to its effectiveness in treating various types of cancers.
2. Technological Advancements: Ongoing research and innovation in liquid embolic agents are contributing to the development of more efficient and safer products. These advancements are expected to enhance treatment outcomes, driving wider adoption of embolization procedures.
3. Minimally Invasive Procedures: The growing preference for minimally invasive treatments, which offer shorter recovery times and fewer complications, is fueling demand for liquid embolic products. Embolization procedures are gaining popularity in medical settings, further boosting market growth.

Market Restraints: Challenges to Overcome

Despite the positive growth outlook, several challenges may hinder the progress of the liquid embolic market:

1. High Risk of Complications: The risks associated with liquid embolic procedures, such as the potential for targeting the wrong blood vessels, balloon deflation, and catheter entrapment, can limit market growth. These complications could deter some healthcare providers from opting for liquid embolic therapies.
2. Limited Manufacturers: The market is dominated by a few manufacturers, creating intense competition and limiting the availability of alternative solutions. This could slow down innovation and restrict the entry of new players into the market.
3. Cost Constraints: Liquid embolic products and the associated procedures are expensive, which could be a barrier for patients in regions with lower healthcare budgets. The high cost of these treatments may limit their accessibility, especially in emerging economies.

Market Opportunities: Emerging Trends and Future Potential

The liquid embolic market presents several opportunities for growth:

1. Expansion into New Indications: As more clinical research is conducted, liquid embolic products are expected to find use in treating a wider range of conditions beyond neurovascular applications. This includes tumor embolization for various types of cancers, where liquid embolic agents could play a crucial role.
2. Rising Demand in Emerging Markets: Countries in Asia-Pacific, particularly South Korea and China, are expected to see significant growth in the liquid embolic market due to the increasing prevalence of cardiovascular diseases and the rising demand for advanced medical treatments.
3. Advancements in R&D: Companies investing in the research and development of new liquid embolic agents, with enhanced efficacy and lower risks, stand to gain a significant market share. Innovations in drug delivery systems and product formulations could open up new opportunities for market expansion.

Reasons to Buy the Report

✔ Gain a comprehensive understanding of the liquid embolic market, including growth trends, opportunities, and challenges.
✔ Access detailed market statistics, forecasts, and insights for the period 2021-2031.
✔ Identify key players and learn about the latest developments in the industry.
✔ Understand the regional dynamics driving growth in North America, Europe, and Asia-Pacific.
✔ Discover the factors contributing to the growing demand for liquid embolic products across various therapeutic areas.

Company Insights: Key Players and Recent Developments

Key Players Operating in the Liquid Embolic Market

1. Medtronic
2. Johnson & Johnson
3. Stryker Corporation
4. Terumo Corporation
5. Merit Medical Systems, Inc.

Recent Developments

• In 2021, Medtronic launched an advanced liquid embolic agent to treat brain arteriovenous malformations, further strengthening its market position.
• Stryker Corporation announced a strategic acquisition of a leading player in the embolization device space, expanding its product portfolio.

Conclusion

The liquid embolic market is poised for significant growth over the coming years, fueled by rising demand for minimally invasive procedures and advancements in embolic agents. However, challenges such as procedure risks and high treatment costs must be addressed to ensure continued expansion. Companies in this space have abundant opportunities to tap into emerging markets and new therapeutic applications, positioning themselves for success in the evolving healthcare landscape.

About Persistence Market Research:

At Persistence Market Research, we specialize in creating research studies that serve as strategic tools for driving business growth. Established as a proprietary firm in 2012, we have evolved into a registered company in England and Wales in 2023 under the name Persistence Research & Consultancy Services Ltd. With a solid foundation, we have completed over 3600 custom and syndicate market research projects, and delivered more than 2700 projects for other leading market research companies' clients.

Our approach combines traditional market research methods with modern tools to offer comprehensive research solutions. With a decade of experience, we pride ourselves on deriving actionable insights from data to help businesses stay ahead of the competition. Our client base spans multinational corporations, leading consulting firms, investment funds, and government departments. A significant portion of our sales comes from repeat clients, a testament to the value and trust we've built over the years.

Contact Us:

Persistence Market Research
G04 Golden Mile House, Clayponds Lane
Brentford, London, TW8 0GU UK
USA Phone: +1 646-878-6329
UK Phone: +44 203-837-5656
Email: sales@persistencemarketresearch.com
Web: https://www.persistencemarketresearch.com

This release was published on openPR.